The need for an inactivated Venezuelan equine encephalomyelitis (VEE) vaccine is manifold. The currently employed attenuated (TC-83) VEE vaccine (4. 9). although highly protective, causes mild to moderate systemic reactions in 20 to 40% of human vaccinees (1; P. J. Bartelloni, personal communication). Based on our experience with inactivated Western and Eastern equine encephalomyelitis (WEE, EEE) vaccines in man (2, 3) . one tan anticipate that a VEE vaccine, similarly prepared, would be of equally low reactogenicity. Moreover, a VEE vaccine could be incorporated with existing inactivated WEE (2) and EEE (10) vaccines to achieve a trivalent product. This combined immunogen would be of logistical advantage for use in at-risk laboratory personnel or field personnel as well as for Equidae. the significant amplifying hosts for VEE.
The need for an inactivated VEE vaccine has been given greater impetus due to the presence of epizootic VEE in the United States and the above-cited observations. This paper describes the development of such a vaccine. one guinea pig passage followed by 13 passages in embryonated hens' eggs (12) . The 13th egg passage material was grown in rolling-bottle cultures of chicken embryo cells (CEO to produce seed virus for vaccine production. A 20/7 suspension of the 13th passage chicken embryo preparation was used as challenge virus for potency assays. Virtu titration. Three-week-old or 1-to 3-day-old white mice (CD-I strain of Charles River Mouse Farms, Wilmington, Mass.) were inoculated intracerebrally lie) with 0.03 ml of log u dilutions of virus in cold phosphate-buffered saline (pH 7.2) containing 1% normal rabbit serum. Six mice were used for each dilution. After a 10-day observation period, titration end points were determined by the method of Reed and Muench (14) and are expressed as median lethal doses (LD i0 ) per ml.
MATERIALS AND METHODS
Cell cultures. Rolling-bottle (280 mm; Bellco Glass. Inc., Vineland, N.J.) cultures of CEC were prepared as previously described (51. Cultures «ere incubated at 35 C until confluent cell sheets were obtained (18 to 24 hr). Growth medium was replaced with a maintenance medium (MM) consisting of serum-free medium 199 containing 0.25$ human serum albumin (USP) plus 100 >.
•{ each of neomycin (USP) and streptomycin (USP) per ml. and the cultures were incubated an additional 20 to 24 hr at 35 C.
Inoculation of cell cultures. MM was decanted from cultures, and residual fluids were drained from t',:a cell sheets. The infecting virus in 10 ml of MM Tests for safety, toxicity, and sterility. Representative lots of vaccine were tested in accordance with current U.S. government regulations (111. Testing was carried out as previously described (10). Virus inactivation. Samples were taken at regular intervals during the period of inactivation and titrated immediately in 1 -to 3-day-old mice. Control virus harvests subjected only to 37 C for similar periods were also included. Typical rates of inactivation for the two Formalin concentrations are shown in Table 3 . With 0.05"^ Formalin, inactivation was complete between 8 to 10 hr. Use of 0.1'; Formalin decreased the inactivation period to between 6 to 8 hr.
RESULTS
Effect of Formalin concentration and length of inactivation period on vaccine potency. Thirty small lots of VEE vaccine were prepared by using either 0.05 or 0.11 Formalin with inactivation periods of 24 to 96 hr. Table 4 is a summary of the results of single-dose potency assays performed on these vaccines. These data indicate thai VEE virus is stable antigenicaily. even after treatment with 0.1"? Formalin for 96 hr at 37 ('.
Selected lots of VEE vaccine were subjected to testing prior to final processing into multidose containers and were shown to be safe, sterile, and nontoxic. inactivation (7, 16, 18) . In future studies, selected lots of inactivated Trinidad VEE vaccine will be tested in Equidae to establish parameters for volume and number of doses required, interval between doses, persistence of immunity, and effectiveness as a "booster" in equines previously immunized with attenuated VEE vaccine as well as in offspring of the latter.
DISCUSSION

